文献速递疝与腹壁外科围术期管理与 ERAS

聚-4-羟基丁酸酯补片用于CDC I类高危腹壁及切口疝修补的前瞻性18个月随访评估

Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up.
PubMed 文献 · Surg Endosc · 2017-10-23

这项前瞻性多中心研究评估了高危患者在CDC I类条件下使用P4HB可吸收补片行腹壁或切口疝修补的结局。P4HB补片在高危疝修补中显示出积极结局和较低的疝复发率。

要点

  • 高危VIHR使用P4HB补片18个月疝复发率为9%。
  • 术后伤口感染率9%,需干预的血清肿发生率6%。
  • 36个月长期随访仍在进行中。

核心结论

  • 高危患者使用P4HB补片行腹壁或切口疝修补在18个月时显示出积极结局和较低的疝复发率。

主要发现

  • 术后伤口感染发生于11例(9%),需干预的血清肿7例(6%),疝复发11例(9%)。
  • 95例(79%)受试者完成18个月随访。
  • 缺损面积115.7±80.6 cm2,补片面积580.9±216.1 cm2。
  • 合并症包括肥胖95例(78.5%)、高血压72例(59.5%)、心血管疾病42例(34.7%)、糖尿病40例(33.1%)、COPD 34例(28.1%)。
  • 疝类型包括原发性切口疝54例(45%)、复发性切口疝35例(29%)、原发性腹壁疝17例(14%)、复发性腹壁疝15例(12%)。

关键数值与推荐

  • 纳入标准:CDC I类、缺损10-350 cm2、既往修补≤3次、至少1项高危标准(肥胖BMI 30-40 kg/m2、主动吸烟、COPD、糖尿病、免疫抑制、冠心病、慢性皮质类固醇使用、低白蛋白血症、高龄、肾功能不全)。

临床怎么用

  • 对于符合CDC I类且具有高危因素的腹壁或切口疝患者,可考虑使用P4HB可吸收补片进行修补。

局限性

  • 18个月随访完成率为79%,长期36个月随访尚未完成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term resorbable mesh represents a promising technology for complex ventral and incisional hernia repair (VIHR). Preclinical studies indicate that poly-4-hydroxybutyrate (P4HB) resorbable mesh supports strength restoration of the abdominal wall. This study evaluated outcomes of high-risk subjects undergoing VIHR with P4HB mesh. METHODS: This was a prospective, multi-institutional study of subjects undergoing retrorectus or onlay VIHR. Inclusion criteria were CDC Class I, defect 10-350 cm2, ≤ 3 prior repairs, and ≥ 1 high-risk criteria (obesity (BMI: 30-40 kg/m2), active smoker, COPD, diabetes, immunosuppression, coronary artery disease, chronic corticosteroid use, hypoalbuminemia, advanced age, and renal insufficiency). Physical exam and/or quality of life surveys were performed at regular intervals through 18 months (to date) with longer-term, 36-month follow-up ongoing. RESULTS: One hundred and twenty-one subjects (46M, 75F) with an age of 54.7 ± 12.0 years and BMI of 32.2 ± 4.5 kg/m2 (mean ± SD), underwent VIHR. Comorbidities included the following: obesity (n = 95, 78.5%), hypertension (n = 72, 59.5%), cardiovascular disease (n = 42, 34.7%), diabetes (n = 40, 33.1%), COPD (n = 34, 28.1%), malignancy (n = 30, 24.8%), active smoker (n = 28, 23.1%), immunosuppression (n = 10, 8.3%), chronic corticosteroid use (n = 6, 5.0%), advanced age (n = 6, 5.0%), hypoalbuminemia (n = 3, 2.5%), and renal insufficiency (n = 1, 0.8%). Hernia types included the following: primary ventral (n = 17, 14%), primary incisional (n = 54, 45%), recurrent ventral (n = 15, 12%), and recurrent incisional hernia (n = 35, 29%). Defect and mesh size were 115.7 ± 80.6 and 580.9 ± 216.1 cm2 (mean ± SD), respectively. Repair types included the following: retrorectus (n = 43, 36%), retrorectus with additional myofascial release (n = 45, 37%), onlay (n = 24, 20%), and onlay with additional myofascial release (n = 8, 7%). 95 (79%) subjects completed 18-month follow-up to date. Postoperative wound infection, seroma requiring intervention, and hernia recurrence occurred in 11 (9%), 7 (6%), and 11 (9%) subjects, respectively. CONCLUSIONS: High-risk VIHR with P4HB mesh demonstrated positive outcomes and low incidence of hernia recurrence at 18 months. Longer-term 36-month follow-up is ongoing.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Roth JS, Anthone GJ, Selzer DJ, et al. Prospective evaluation of poly-4-hydroxybutyrate mesh in CDC class I/high-risk ventral and incisional hernia repair: 18-month follow-up. Surg Endosc. 2017. PMID: 29063307. doi:10.1007/s00464-017-5886-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。